BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28961023)

  • 1. In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
    Ni XL; Chen LX; Zhang H; Yang B; Xu S; Wu M; Liu J; Yang LL; Chen Y; Fu SZ; Wu JB
    Drug Deliv; 2017 Nov; 24(1):1501-1512. PubMed ID: 28961023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
    Lai KC; Chueh FS; Hsiao YT; Cheng ZY; Lien JC; Liu KC; Peng SF; Chung JG
    Toxicol Appl Pharmacol; 2019 Nov; 382():114734. PubMed ID: 31470033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
    Satari N; Taymouri S; Varshosaz J; Rostami M; Mirian M
    Drug Dev Ind Pharm; 2020 Aug; 46(8):1265-1277. PubMed ID: 32594775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer.
    Wen Q; Zhang Y; Muluh TA; Xiong K; Wang B; Lu Y; Wu Z; Liu Y; Shi H; Xiao S; Fu S
    Int J Biol Macromol; 2021 Dec; 193(Pt A):228-237. PubMed ID: 34688683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
    Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
    Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer.
    Garizo AR; Castro F; Martins C; Almeida A; Dias TP; Fernardes F; Barrias CC; Bernardes N; Fialho AM; Sarmento B
    J Control Release; 2021 Sep; 337():329-342. PubMed ID: 34311024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
    PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.
    Godugu C; Doddapaneni R; Patel AR; Singh R; Mercer R; Singh M
    Pharm Res; 2016 Jan; 33(1):137-54. PubMed ID: 26286185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer.
    Sherif AY; Harisa GI; Shahba AA; Alanazi FK; Qamar W
    Molecules; 2023 Jan; 28(1):. PubMed ID: 36615641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.
    Sherif AY; Harisa GI; Alanazi FK; Nasr FA; Alqahtani AS
    AAPS PharmSciTech; 2022 Jul; 23(6):183. PubMed ID: 35773422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies.
    Harisa GI; Sherif AY; Alanazi FK; Ali EA; Omran GA; Nasr FA; Attia SM; Alqahtani AS
    Colloids Surf B Biointerfaces; 2023 Mar; 223():113148. PubMed ID: 36706479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
    Dal Bello MG; Alama A; Barletta G; Coco S; Truini A; Vanni I; Boccardo S; Genova C; Rijavec E; Biello F; Bottoni G; Sambuceti G; Grossi F
    Int J Cancer; 2015 Dec; 137(12):2947-58. PubMed ID: 26089022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression.
    Xiong Z; Tong T; Xie Z; Yu S; Zhuang R; Jia Q; Peng S; Li B; Xie J; Li K; Wu J; Huang H
    Biomater Sci; 2024 Jan; 12(3):650-659. PubMed ID: 38168678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
    Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
    Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization.
    Kola Srinivas NS; Verma R; Pai Kulyadi G; Kumar L
    Int J Nanomedicine; 2017; 12():15-28. PubMed ID: 28031710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel liposomal gefitinib (L-GEF) formulations.
    Zhou X; Yung B; Huang Y; Li H; Hu X; Xiang G; Lee RJ
    Anticancer Res; 2012 Jul; 32(7):2919-23. PubMed ID: 22753756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.
    Zhao L; Yang G; Shi Y; Su C; Chang J
    J Nanobiotechnology; 2015 Sep; 13():57. PubMed ID: 26395758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.
    Elzayat EM; Sherif AY; Nasr FA; Attwa MW; Alshora DH; Ahmad SF; Alqahtani AS
    Materials (Basel); 2023 Jul; 16(15):. PubMed ID: 37570067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.
    Sherif AY; Harisa GI; Alanazi FK; Nasr FA; Alqahtani AS
    Int J Nanomedicine; 2022; 17():3287-3311. PubMed ID: 35924261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles.
    Yugui F; Wang H; Sun D; Zhang X
    Biomed Pharmacother; 2019 Jun; 114():108820. PubMed ID: 30951947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.